A lawsuit was filed on behalf of investors in Eagle Pharmaceuticals Inc (NASDAQ:EGRX) shares over alleged securities laws violations and NASDAQ:EGRX investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 06/06/2016 -- An investor, who purchased shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX), filed a lawsuit in New Jersey over alleged Securities Laws violations by Woodcliff Lake, NJ based Eagle Pharmaceuticals Inc in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) have certain options and for certain investors are short and strict deadlines running. Deadline: August 1, 2016. NASDAQ:EGRX investors should contact the Shareholders Foundation at firstname.lastname@example.org or call 858-779-1554.
According to the complaint the plaintiff alleges on behalf of purchasers of Eagle Pharmaceuticals Inc (NASDAQ:EGRX) common shares between February 23, 2016 and March 18, 2016, that the defendants violated Federal Securities Laws.
Shares of Eagle Pharmaceuticals Inc reached as high as $97.17 per share in December 2015.
On February 25, 2016, Eagle Pharmaceuticals Inc reported its fourth quarter and full year 2015 results. Eagle Pharmaceuticals Inc reported that its Total Revenue rose from $19.10 million for the 12 months period that ended on September 30, 2014 to $66.23 million for the 12 months period that ended on December 31, 2015 and that its Net Loss of $17.98 million for the 12 months period that ended on September 30, 2014 turned into a Net Income of $2.57 million for the 12 months period that ended on December 31, 2015.
On February 25, 2016, Eagle Pharmaceuticals' CEO stated, regarding the pending New Drug Application ("NDA") for the Company's anticoagulant drug KANGIO™, "We have been interacting with FDA and we are preparing for launch, everything seems to be on track for a March 19 approval, and we anticipate shipping in late Q1 or early Q2."
Then, on March 18, 2016, Eagle Pharmaceuticals announced that it had received a Complete Response Letter from the FDA stating that the FDA "cannot approve the application in its present form and requested additional information" regarding the substances used in KANGIO™.
Shares of Eagle Pharmaceuticals declined to as low as $35.10 per share on March 28, 2016.
On June 3, 2016, NASDAQ:EGRX shares closed at $43.78 per share.
Those who purchased shares of Eagle Pharmaceuticals Inc have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego